Allogene Therapeutics (NASDAQ:ALLO) EVP Sells $63,189.00 in Stock

by · The Cerbat Gem

Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Free Report) EVP Zachary Roberts sold 35,700 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $1.77, for a total value of $63,189.00. Following the completion of the transaction, the executive vice president owned 581,166 shares of the company’s stock, valued at $1,028,663.82. The trade was a 5.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Zachary Roberts also recently made the following trade(s):

  • On Wednesday, January 21st, Zachary Roberts sold 26,269 shares of Allogene Therapeutics stock. The shares were sold at an average price of $1.56, for a total value of $40,979.64.

Allogene Therapeutics Trading Up 3.4%

Shares of NASDAQ:ALLO traded up $0.06 during trading on Wednesday, hitting $1.80. 6,031,813 shares of the company were exchanged, compared to its average volume of 6,604,055. Allogene Therapeutics, Inc. has a fifty-two week low of $0.86 and a fifty-two week high of $3.78. The stock has a market cap of $404.51 million, a price-to-earnings ratio of -1.84 and a beta of 0.60. The firm has a fifty day moving average price of $1.51 and a two-hundred day moving average price of $1.32.

Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last released its earnings results on Thursday, November 6th. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.04. As a group, research analysts predict that Allogene Therapeutics, Inc. will post -1.28 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. UBS Group started coverage on shares of Allogene Therapeutics in a research note on Wednesday, January 7th. They issued a “buy” rating and a $8.00 target price for the company. JPMorgan Chase & Co. reiterated an “underweight” rating on shares of Allogene Therapeutics in a research note on Friday, October 10th. Wall Street Zen raised Allogene Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, November 28th. Citizens Jmp raised Allogene Therapeutics from a “market perform” rating to an “outperform” rating and set a $5.00 price target for the company in a report on Friday, January 9th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allogene Therapeutics in a research report on Wednesday, October 8th. Ten equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $8.40.

Read Our Latest Stock Report on Allogene Therapeutics

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Goldman Sachs Group Inc. increased its position in Allogene Therapeutics by 177.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 5,853,974 shares of the company’s stock worth $8,547,000 after buying an additional 3,747,397 shares during the period. Millennium Management LLC grew its stake in shares of Allogene Therapeutics by 125.6% in the third quarter. Millennium Management LLC now owns 3,390,026 shares of the company’s stock valued at $4,204,000 after acquiring an additional 1,887,302 shares in the last quarter. Two Sigma Investments LP increased its position in Allogene Therapeutics by 109.7% during the third quarter. Two Sigma Investments LP now owns 3,383,644 shares of the company’s stock worth $4,196,000 after acquiring an additional 1,770,419 shares during the period. UBS Group AG increased its position in Allogene Therapeutics by 75.1% during the third quarter. UBS Group AG now owns 3,571,157 shares of the company’s stock worth $4,428,000 after acquiring an additional 1,532,238 shares during the period. Finally, Primecap Management Co. CA raised its stake in Allogene Therapeutics by 23.8% in the 3rd quarter. Primecap Management Co. CA now owns 7,079,308 shares of the company’s stock worth $8,778,000 after purchasing an additional 1,360,168 shares in the last quarter. 83.63% of the stock is owned by institutional investors and hedge funds.

About Allogene Therapeutics

(Get Free Report)

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.

Recommended Stories